Related scientific articles (all)

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.

Authors : De Jaeghere EA, Tuyaerts S, Van Nuffel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, van de Vijver KK, Amant F, Vandecasteele K, Denys HG
Year : 2023
Journal : Cancer Immunol Immunother
Volume : 72
Pages : 475-491

Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials.

Authors : Perez-Gracia JL, Penel N, Calvo E, Awada A, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF, Castelo-Branco L, Bodoky G, Lolkema MP, Di Nicola M, Casali P, Giuliani R, Pentheroudakis G
Year : 2023
Journal : Ann Oncol
Volume : 34
Pages : 70-77

Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy.

Authors : Jungels C, Pita JM, Costante G
Year : 2023
Journal : Curr Opin Oncol
Volume : 35
Pages : 1-9

ASO Visual Abstract: Prognostic Value of Preoperative Serological Biomarkers in Patients Undergoing Curative-Intent Cytoreductive Surgery for Colorectal Cancer Peritoneal Metastases.

Authors : El Asmar A, Delcourt M, Kamden L, Khaled C, Bohlok A, Moreau M, Sclafani F, Donckier V, Liberale G
Year : 2023
Journal : Ann Surg Oncol
Volume : 30
Pages : 1872-1873

ESPEN practical guideline: Home parenteral nutrition.

Authors : Pironi L, Boeykens K, Bozzetti F, Joly F, Klek S, Lal S, Lichota M, Mühlebach S, Van Gossum A, Wanten G, Wheatley C, Bischoff SC
Year : 2023
Journal : Clin Nutr
Volume : 42
Pages : 411-430

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.

Authors : Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA
Year : 2023
Journal : JAMA Oncol
Volume : 9
Pages : 29-39

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.

Authors : Wang X, Collet L, Rediti M, Debien V, De Caluwé A, Venet D, Romano E, Rothé F, Sotiriou C, Buisseret L
Year : 2023
Journal : J Clin Med
Volume : 12

Liquid biopsy accelerates precision medicine.

Authors : Amato O, Aftimos P, Ignatiadis M
Year : 2023
Journal : Ann Oncol

[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.

Authors : Iqbal R, Yaqub M, Bektas HO, Oprea-Lager DE, de Vries EGE, Glaudemans AWJM, Aftimos P, Gebhart G, Beelen AP, Schuit RC, Windhorst AD, Boellaard R, Menke-van der Houven van Oordt CW
Year : 2023
Journal : Clin Cancer Res

First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.

Authors : Harding JJ, Jungels C, Machiels JP, Smith DC, Walker C, Ji T, Jiang P, Li X, Asatiani E, van Cutsem E, Abou-Alfa GK
Year : 2023
Journal : Target Oncol

Pre-existing evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.

Authors : Bregni G, Trevisi E, Saude Conde R, Vanhooren M, Akin Telli T, Assaf I, Hendlisz A, Di Maio M, Sclafani F
Year : 2023
Journal : J Natl Cancer Inst

Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets.

Authors : Zambelli A, Sgarra R, De Sanctis R, Agostinetto E, Santoro A, Manfioletti G
Year : 2022
Journal : Expert Opin Ther Targets
Volume : 26
Pages : 557-573

Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.

Authors : Dal Lago L, Uwimana AL, Coens C, Vuylsteke P, Curigliano G, Brouwers B, Jagiello-Gruszfeld A, Altintas S, Tryfonidis K, Poncet C, Bottomley A, Sousa B, Brain E, Wildiers H
Year : 2022
Journal : J Geriatr Oncol
Volume : 13
Pages : 582-593

Delivering precision oncology to patients with cancer.

Authors : Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, Geissler J, Husereau D, Martinez-Lopez I, Normanno N, Reis-Filho JS, Stefani S, Thomas DM, Westphalen CB, Voest E
Year : 2022
Journal : Nat Med
Volume : 28
Pages : 658-665

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.

Authors : Chang CA, Jen J, Jiang S, Sayad A, Mer AS, Brown KR, Nixon AML, Dhabaria A, Tang KH, Venet D, Sotiriou C, Deng J, Wong KK, Adams S, Meyn P, Heguy A, Skok JA, Tsirigos A, Ueberheide B, Moffat J, Singh A, Haibe-Kains B, Khodadadi-Jamayran A, Neel BG
Year : 2022
Journal : Cancer Discov
Volume : 12
Pages : 1022-1045

Efficacy of pharmacologic treatment for treating gastrointestinal angiodysplasias-related bleeding: a systematic review and meta-analysis.

Authors : Gkolfakis P, Fostier R, Tziatzios G, Lazaridis N, Fernandez Y Viesca M, Facciorusso A, Despott E, Triantafyllou K, Devière J, Arvanitakis M
Year : 2022
Journal : Eur J Gastroenterol Hepatol
Volume : 34
Pages : 1021-1030

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma.

Authors : Najem A, Soumoy L, Sabbah M, Krayem M, Awada A, Journe F, Ghanem GE
Year : 2022
Journal : Cells
Volume : 11

Results of a single-arm pilot study of (32)P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy.

Authors : Ross PJ, Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, Nagrial AM, Bartholomeusz D, Hendlisz A, Ajithkumar T, Iwuji C, Wilson NE, Turner DM, James DC, Young E, Harris MT
Year : 2022
Journal : ESMO Open
Volume : 7
Pages : 100356

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer.

Authors : Agostinetto E, Jacobs F, Debien V, De Caluwé A, Pop CF, Catteau X, Aftimos P, de Azambuja E, Buisseret L
Year : 2022
Journal : Cancers (Basel)
Volume : 14

Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.

Authors : Longo-Muñoz F, Castellano D, Alexandre J, Chawla SP, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Moreno V, Sanz-García E, Awada A, Santaballa A, Subbiah V
Year : 2022
Journal : Eur J Cancer
Volume : 172
Pages : 340-348